RNA-Nucleic Acid-Derived Neurotrophic Factor (RNR1): A Potential Drug Target for Neurodegenerative Diseases

Target Name: RNR1

NCBI ID: G4549

RNR1

RNA-Nucleic Acid-Derived Neurotrophic Factor (RNR1): A Potential Drug Target for Neurodegenerative Diseases

RNA-Nucleic Acid-Derived Neurotrophic Factor (RNR1) is a protein that is expressed in various tissues of the brain, including the nervous system, and is considered a potential drug target or biomarker. The RNA-Nucleic Acid-Derived Neurotrophic Factor (RNR1) is a transmembrane protein that is composed of 116 amino acid residues. It has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic neurodegenerative diseases.

RNR1 is expressed in various tissues of the brain, including the prefrontal cortical cortex, basal ganglia, and cerebellum. It is also expressed in other tissues, including the heart, skeletal muscles, and pancreas.NRN1 has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic neurodegenerative diseases.

One of the most significant functions of RNR1 is its role in the development and progression of Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disease that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. Studies have shown that RNR1 is involved in the development and progression of Alzheimer's disease by regulating the production of pro-inflammatory molecules, such as TNF-alpha and IL-1尾.

In addition to its role in the development and progression of Alzheimer's disease, RNR1 has also been shown to be involved in the treatment of neurodegenerative diseases. For example, studies have shown that RNA-Nucleic Acid-Derived Neurotrophic Factor (RNR1) can be used to treat neurodegenerative diseases by increasing the levels of brain-derived neurotrophic factor (BDNF) in the brain. BDNF is a protein that is produced by the brain and has been shown to play a role in the treatment of neurodegenerative diseases.

NRN1 has also been shown to play a role in the development and progression of Parkinson's disease. Parkinson's disease is a progressive neurodegenerative disease that is characterized by the accumulation of neuro-active molecules, such as dopamine, in the brain. Studies have shown that RNR1 is involved in the development and progression of Parkinson's disease by regulating the production of pro-inflammatory molecules, such as PDGF-BB.

In conclusion, RNA-Nucleic Acid-Derived Neurotrophic Factor (RNR1) is a protein that is expressed in various tissues of the brain and is considered a potential drug target or biomarker. Its role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic neurodegenerative diseases has been well-documented. Further research is needed to fully understand the role of RNR1 in the treatment of neurodegenerative diseases.

Protein Name: Mitochondrially Encoded 12S RNA

Functions: Regulates insulin sensitivity and metabolic homeostasis (PubMed:25738459, PubMed:33468709). Inhibits the folate cycle, thereby reducing de novo purine biosynthesis which leads to the accumulation of the de novo purine synthesis intermediate 5-aminoimidazole-4-carboxamide (AICAR) and the activation of the metabolic regulator 5'-AMP-activated protein kinase (AMPK) (PubMed:25738459). Protects against age-dependent and diet-induced insulin resistance as well as diet-induced obesity (PubMed:25738459). In response to metabolic stress, translocates to the nucleus where it binds to antioxidant response elements (ARE) present in the promoter regions of a number of genes and plays a role in regulating nuclear gene expression in an NFE2L2-dependent manner and increasing cellular resistance to metabolic stress (PubMed:29983246). Increases mitochondrial respiration and levels of CPT1A and cytokines IL1B, IL6, IL8, IL10 and TNF in senescent cells (PubMed:29886458). Increases activity of the serine/threonine protein kinase complex mTORC2 and reduces activity of the PTEN phosphatase, thus promoting phosphorylation of AKT (PubMed:33554779). This promotes AKT-mediated phosphorylation of transcription factor FOXO1 which reduces FOXO1 activity, leading to reduced levels of MSTN and promotion of skeletal muscle growth (PubMed:33554779). Promotes osteogenic differentiation of bone marrow mesenchymal stem cells via the TGFB/SMAD pathway (PubMed:30468456). Promotes osteoblast proliferation and osteoblast synthesis of type I collagens COL1A1 and COL1A2 via the TGFB/SMAD pathway (PubMed:31081069)

The "RNR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets